世界の肺動脈性肺高血圧症（PAH）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Pulmonary Arterial Hypertension (PAH) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4863
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、90ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、肺動脈性肺高血圧症（PAH）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（プロスタサイクリン＆プロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・肺動脈性肺高血圧症（PAH）の市場動向
・企業の競争状況、市場シェア
・肺動脈性肺高血圧症（PAH）の種類別市場規模（プロスタサイクリン＆プロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）
・肺動脈性肺高血圧症（PAH）の用途別市場規模（病院、診療所）
・肺動脈性肺高血圧症（PAH）の北米市場規模2016-2027（アメリカ、カナダ）
・肺動脈性肺高血圧症（PAH）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・肺動脈性肺高血圧症（PAH）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・肺動脈性肺高血圧症（PAH）の中南米市場規模2016-2027（メキシコ、ブラジル）
・肺動脈性肺高血圧症（PAH）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Actelion、Gilead Sciences、United Therapeutics、GlaxoSmithKline、Pfizer、Bayer、Arena）
・結論

Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market
The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pulmonary Arterial Hypertension (PAH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pulmonary Arterial Hypertension (PAH) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pulmonary Arterial Hypertension (PAH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pulmonary Arterial Hypertension (PAH) market.

Global Pulmonary Arterial Hypertension (PAH) Scope and Market Size
Pulmonary Arterial Hypertension (PAH) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5

Segment by Application
Hospital
Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Prostacyclin and Prostacyclin Analogs
1.2.3 SGC Stimulators
1.2.4 ERA
1.2.5 PDE-5
1.3 Market by Application
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2016-2027)
2.2 Pulmonary Arterial Hypertension (PAH) Growth Trends by Regions
2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Share by Regions (2016-2021)
2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Regions (2022-2027)
2.3 Pulmonary Arterial Hypertension (PAH) Industry Dynamic
2.3.1 Pulmonary Arterial Hypertension (PAH) Market Trends
2.3.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
2.3.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
2.3.4 Pulmonary Arterial Hypertension (PAH) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue
3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2016-2021)
3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2016-2021)
3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
3.4 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
3.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2020
3.5 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
3.6 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
3.7 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2016-2021)
4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2022-2027)

5 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2016-2021)
5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2016-2027)
6.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type
6.2.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021)
6.2.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027)
6.2.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2027)
6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application
6.3.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021)
6.3.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027)
6.3.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2027)
6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country
6.4.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021)
6.4.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2016-2027)
7.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type
7.2.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021)
7.2.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027)
7.2.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2027)
7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application
7.3.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021)
7.3.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027)
7.3.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2027)
7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country
7.4.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021)
7.4.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2016-2027)
8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type
8.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2027)
8.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application
8.3.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2027)
8.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region
8.4.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2016-2027)
9.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type
9.2.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021)
9.2.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027)
9.2.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2027)
9.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application
9.3.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021)
9.3.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027)
9.3.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2027)
9.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country
9.4.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021)
9.4.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2016-2027)
10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type
10.2.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2027)
10.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application
10.3.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2027)
10.4 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country
10.4.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Actelion
11.1.1 Actelion Company Details
11.1.2 Actelion Business Overview
11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
11.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.1.5 Actelion Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
11.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.2.5 Gilead Sciences Recent Development
11.3 United Therapeutics
11.3.1 United Therapeutics Company Details
11.3.2 United Therapeutics Business Overview
11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
11.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.3.5 United Therapeutics Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
11.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.4.5 GlaxoSmithKline Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
11.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 Bayer
11.6.1 Bayer Company Details
11.6.2 Bayer Business Overview
11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
11.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.6.5 Bayer Recent Development
11.7 Arena
11.7.1 Arena Company Details
11.7.2 Arena Business Overview
11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
11.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
11.7.5 Arena Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Prostacyclin and Prostacyclin Analogs
Table 3. Key Players of SGC Stimulators
Table 4. Key Players of ERA
Table 5. Key Players of PDE-5
Table 6. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Pulmonary Arterial Hypertension (PAH) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Pulmonary Arterial Hypertension (PAH) Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions (2016-2021)
Table 10. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions (2022-2027)
Table 12. Pulmonary Arterial Hypertension (PAH) Market Trends
Table 13. Pulmonary Arterial Hypertension (PAH) Market Drivers
Table 14. Pulmonary Arterial Hypertension (PAH) Market Challenges
Table 15. Pulmonary Arterial Hypertension (PAH) Market Restraints
Table 16. Global Pulmonary Arterial Hypertension (PAH) Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players (2016-2021)
Table 18. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2020)
Table 19. Ranking of Global Top Pulmonary Arterial Hypertension (PAH) Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
Table 23. Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2016-2021)
Table 27. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2016-2021)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2022-2027) & (US$ Million)
Table 63. Actelion Company Details
Table 64. Actelion Business Overview
Table 65. Actelion Pulmonary Arterial Hypertension (PAH) Product
Table 66. Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 67. Actelion Recent Development
Table 68. Gilead Sciences Company Details
Table 69. Gilead Sciences Business Overview
Table 70. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product
Table 71. Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 72. Gilead Sciences Recent Development
Table 73. United Therapeutics Company Details
Table 74. United Therapeutics Business Overview
Table 75. United Therapeutics Pulmonary Arterial Hypertension (PAH) Product
Table 76. United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 77. United Therapeutics Recent Development
Table 78. GlaxoSmithKline Company Details
Table 79. GlaxoSmithKline Business Overview
Table 80. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product
Table 81. GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 82. GlaxoSmithKline Recent Development
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Pulmonary Arterial Hypertension (PAH) Product
Table 86. Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 87. Pfizer Recent Development
Table 88. Bayer Company Details
Table 89. Bayer Business Overview
Table 90. Bayer Pulmonary Arterial Hypertension (PAH) Product
Table 91. Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 92. Bayer Recent Development
Table 93. Arena Company Details
Table 94. Arena Business Overview
Table 95. Arena Pulmonary Arterial Hypertension (PAH) Product
Table 96. Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2016-2021) & (US$ Million)
Table 97. Arena Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Share by Type: 2020 VS 2027
Figure 2. Prostacyclin and Prostacyclin Analogs Features
Figure 3. SGC Stimulators Features
Figure 4. ERA Features
Figure 5. PDE-5 Features
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Pulmonary Arterial Hypertension (PAH) Report Years Considered
Figure 10. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions: 2020 VS 2027
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions (2022-2027)
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players in 2020
Figure 15. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2020
Figure 17. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2016-2021)
Figure 18. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2022-2027)
Figure 19. North America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2016-2027)
Figure 21. North America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2016-2027)
Figure 22. North America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2016-2027)
Figure 23. United States Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Type (2016-2027)
Figure 27. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Application (2016-2027)
Figure 28. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Country (2016-2027)
Figure 29. Germany Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Region (2016-2027)
Figure 39. China Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2016-2027)
Figure 47. Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2016-2027)
Figure 48. Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Country (2016-2027)
Figure 49. Mexico Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Country (2016-2027)
Figure 55. Turkey Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Actelion Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 59. Gilead Sciences Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 60. United Therapeutics Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 61. GlaxoSmithKline Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 63. Bayer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 64. Arena Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

以下、関連資料のご紹介

世界の肺動脈性肺高血圧症治療市場規模・現状・予測（2021年-2027年）

Global Pulmonary Arterial Hypertension Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4864 2021年4月 94Pages
QYResearch社発行の本調査資料では、肺動脈性肺高血圧症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺...

世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場規模・現状・予測（2021年-2027年）

Global Chronic Thromboembolic Pulmonary Hypertension Market Size, Status and Forecast 2021-2027
QYR2104Z1329 2021年4月 99Pages
QYResearch社発行の本調査資料では、慢性血栓塞栓性肺高血圧症（CTEPH）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経胸壁心エコー図（TTE）、換気灌流（V / Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影...

世界の3D動脈スピンラベリング（3D ASL）市場規模・現状・予測（2021年-2027年）

Global 3D Arterial Spin Labeling (3D ASL) Market Size, Status and Forecast 2021-2027
QYR2104Z6125 2021年4月 96Pages
QYResearch社発行の本調査資料では、3D動脈スピンラベリング（3D ASL）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（キャッスル（CASL）、PASL）、用途別市場規模（腫瘍、脳血管障害、神経変性疾患、パーキンソン病）、主要地域別...

世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年）

Global Chronic Obstructive Pulmonary Disease Market Size, Status and Forecast 2021-2027
QYR2104Z1323 2021年4月 98Pages
QYResearch社発行の本調査資料では、慢性閉塞性肺疾患（COPD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（気管支拡張薬、糖質コルチコイド、その他）、用途別市場規模（予防、診断、治療）、主要地域別市場規模（北米、アメリカ、ヨーロッパ...

世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年）

Global Chronic Obstructive Pulmonary Disorder Market Size, Status and Forecast 2021-2027
QYR2104Z1326 2021年4月 99Pages
QYResearch社発行の本調査資料では、慢性閉塞性肺疾患（COPD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、ホスホジエステラーゼ-4阻害薬、そ...

世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年）

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, Status and Forecast 2021-2027
QYR2104Z1325 2021年4月 96Pages
QYResearch社発行の本調査資料では、慢性閉塞性肺疾患（COPD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、ホスホジエステラーゼ-4阻害薬、そ...

世界の末梢動脈疾患（PAD）治療薬市場規模・現状・予測（2021年-2027年）

Global Peripheral Arterial Disease (PAD) Drugs Market Size, Status and Forecast 2021-2027
QYR2104Z4518 2021年4月 93Pages
QYResearch社発行の本調査資料では、末梢動脈疾患（PAD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（クロピドグレル（Plavix）、プラスグレル（Effient）、チカグレロル（Brilinta）、ボラパクサール（Zonti...

世界の高眼圧症治療市場規模・現状・予測（2021年-2027年）

Global Ocular Hypertension Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4224 2021年4月 98Pages
QYResearch社発行の本調査資料では、高眼圧症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（高眼圧症、緑内障）、用途別市場規模（病院、専門クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国...

世界の高血圧・心不全治療市場規模・現状・予測（2021年-2027年）

Global Hypertension and Heart Failure Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3000 2021年4月 93Pages
QYResearch社発行の本調査資料では、高血圧・心不全治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（利尿薬、β遮断薬、エース阻害薬、α遮断薬、その他）、用途別市場規模（男性、女性）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジ...

世界の末梢動脈疾患（PAD）治療薬市場規模・現状・予測（2021年-2027年）

Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z4519 2021年4月 99Pages
QYResearch社発行の本調査資料では、末梢動脈疾患（PAD）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗血小板薬、二重抗血小板療法薬、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロ...

世界の肺動脈性肺高血圧症治療市場規模・現状・予測（2021年-2027年） Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries re…
世界の慢性血栓塞栓性肺高血圧症（CTEPH）市場規模・現状・予測（2021年-2027年） Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Heal…
世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年） Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eve…
世界の肺薬市場 2021：企業別、地域別、種類・用途別 The Pulmonary Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, re…
世界の慢性閉塞性肺疾患（COPD）市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disorder (COPD) Market The global Chronic Obstructive Pulmonary Disorder (COPD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy…